Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer.

Trial Profile

Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms PRECEPT
  • Sponsors Amgen
  • Most Recent Events

    • 04 Jun 2012 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Planned end date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top